Novel use of a blend of saccharides including psicose, mannose, fructose and glucose

Abstract

The present invention relates to the use of a blend of saccharides including psicose, mannose, fructose and glucose for increasing the expression of cytokeratin 1 in the skin to enhance the self-defense mechanism of the skin and to maintain skin integrity.

Description

Detailed Description of the Invention

[0001] The present invention relates to the use of a blend of saccharides including psicose, mannose, fructose and glucose for increasing the expression of cytokeratin 1 in the skin to enhance the self-defense mechanism of the skin and maintain skin integrity.

[0002] Keratins are keratin proteins found in the cytoplasmic cytoskeleton of epithelial tissues. These are important components of intermediate filaments and promote the ability of cells to withstand mechanical stress.

[0003] Cytokeratin 1 is the main component of the intermediate filament cytoskeleton in the suprabasal epidermis. In humans, a decrease in the concentration of cytokeratin 1 can lead to exfoliative ichthyosis. Investigating the pathological mechanisms, which are mostly unknown, and the role of keratin in barrier formation and inflammation control, it has been found that cytokeratin 1 is important for maintaining skin integrity and is involved in the inflammatory network of mouse keratinocytes.

[0004] Therefore, there is a continuing need for a component that can specifically stimulate the expression of cytokeratin 1 in skin tissues in the presence of microorganisms, for example, skin colonized by one or more of C. acnes, S. epidermidis, C. striatum and S. aureus.

[0005] While not wishing to be bound by any particular theory or mechanism of action, thus, the enhancement of skin integrity may be due to the presence of cytokeratin 1, which is known to be essential for the proper differentiation of simple and stratified epithelial tissues. Therefore, the blend of saccharides of the present invention can be used to enhance the self-defense mechanism of the skin and maintain skin integrity.

[0006] Accordingly, in the first embodiment, the present invention specifically relates to a composition comprising an effective amount of a blend of saccharides including psicose, mannose, fructose, and glucose for use in dermatological treatment as an agent for increasing the expression of cytokeratin 1 in skin tissue when pathogenic bacteria such as S. aureus are forming colonies or may form colonies. Said use is particularly suitable for strengthening the skin's self-defense mechanism and maintaining skin integrity, especially in the presence of pathogenic bacteria such as S. aureus. Accordingly, said use can specifically reduce and / or attenuate the negative diseases associated with the colonization of the skin by pathogenic bacteria such as S. aureus.

[0007] In a further embodiment, the present invention relates to a method for preventing or treating skin diseases caused by a decrease in the expression of cytokeratin 1 in skin tissue, particularly in skin colonized by pathogenic bacteria, preferably S. aureus, said method comprising a) providing a cosmetic or dermatological composition comprising a blend of saccharides including psicose, mannose, fructose, and glucose; and b) applying to human skin, preferably skin colonized by S. aureus or skin that may be exposed to S. aureus, an amount of said composition sufficient to increase the expression of cytokeratin 1. and

[0008] The increased expression of cytokeratin 1 of the present invention is understood to strengthen the skin's self-defense mechanism and maintain the skin in a healthy state.

[0009] In a further aspect, the present invention relates to a blend of saccharides comprising psicose, mannose, fructose and glucose (and / or a cosmetic or dermatological composition comprising said saccharide blend), which is for use in the prevention and / or treatment of skin diseases associated with a decrease in cytokeratin 1 expression, for use in the treatment of skin diseases in which a decrease in cytokeratin 1 expression contributes to its pathology, and / or symptoms, and / or progression, for use in increasing the expression of cytokeratin 1 in skin tissue, specifically skin that is colonized by, exposed to, or at risk of being exposed to S. aureus (including in a subject in need thereof) and / or for use as a cytokeratin 1 expression promoter.

[0010] In another aspect, there is provided the use of a blend of saccharides comprising psicose, mannose, fructose and glucose (and / or a cosmetic or dermatological composition comprising said saccharide blend), which is for use in the treatment of a disease or disorder associated with a decrease in cytokeratin 1 expression, for use in the treatment of a disease / disorder in which a decrease in cytokeratin 1 expression contributes to its pathology, and / or symptoms, and / or progression, for use in the expression of cytokeratin 1 in skin tissue, specifically skin that is colonized by, exposed to, or at risk of being exposed to S. aureus and / or for use as a cytokeratin 1 expression promoter (including in a subject in need thereof).

[0011] In another aspect, there is provided the use of a blend of saccharides comprising psicose, mannose, fructose and glucose (and / or a cosmetic or dermatological composition comprising said saccharide blend), which is for the treatment of a disease or disorder associated with a decrease in cytokeratin 1 expression, a disease or disorder in which a decrease in cytokeratin 1 expression contributes to its pathology, and / or symptoms, and / or progression and / or specifically for the production of an agent for the expression of cytokeratin 1 in skin in which S. aureus is colonizing, has been exposed to or is at risk of being exposed to it (including that in a subject in need thereof).

[0012] In another aspect, there is provided a method for treating a disease or disorder in which a decrease in cytokeratin 1 expression contributes to its pathology, and / or symptoms, and / or progression, the method comprising administering to a subject (such as a subject in need thereof), preferably a subject whose skin has been colonized by, has been exposed to or is at risk of being exposed to S. aureus, an effective amount of a blend of saccharides comprising psicose, mannose, fructose and glucose.

[0013] The present invention also relates to a blend of saccharides comprising psicose, mannose, fructose and glucose as a cytokeratin 1 expression promoter, particularly in skin tissue.

[0014] As used herein, the term "skin" is intended to include the outer surface of a mammal, particularly a human, and this includes the skin and the scalp. The preferred skin in all embodiments of the present invention is facial skin and body skin, for example most preferably facial skin.

[0015] As used herein, the term "prevention" refers to reducing the risk of onset of a skin disease associated with a decrease in cytokeratin 1 expression.

[0016] As used herein, the term "treatment" refers to the amelioration of symptoms of any disease, delay in onset and / or shortening of duration associated with a decrease in cytokeratin 1 expression. Treatment can be prophylactic (cosmetic) or therapeutic. Preferably, the treatment is prophylactic.

[0017] As used herein, the term "cytokeratin 1 expression promoter" refers to a compound capable of stimulating the expression of cytokeratin 1 in skin tissue. The expression of cytokeratin 1 in skin tissue can be decreased by the presence of pathogenic bacteria present on the skin, such as the presence of S. aureus (S. aureus).

[0018] In a particularly advantageous embodiment of the invention, the uses and methods of the invention are carried out on human skin, wherein the microbiome of said skin comprises one or more, preferably all, of Cutibacterium acnes (C. acnes), S. Epidermidis, Corynebacterium striatum (C. striatum) and Staphylococcus aureus (S. aureus). The uses and methods can also be carried out on human skin, wherein the microbiome of said skin comprises one or more, preferably all, of C. acnes, S. Epidermidis and C. striatum, and the human skin is or may be exposed to S. aureus.

[0019] As used herein, the term "effective amount" refers to the amount necessary to obtain a physiological effect. The physiological effect can be achieved by a single dose application or repeated applications. The dose administered will, of course, vary according to known factors such as the physiological characteristics of a particular cosmetic or dermatological composition, including a blend of saccharides including psicose, mannose, fructose and glucose, and its method and route of administration; age, nature and degree of the symptoms; type of concomitant treatment; treatment frequency; and the desired effect, and can be adjusted by those skilled in the art.

[0020] Preferably, the concentration of psicose used in all embodiments of the present invention is in the range of 0.0001 to 0.5% by weight, more preferably in the range of 0.0005 to 0.25% by weight, most preferably in the range of 0.00075 to 0.2% by weight, for example in the range of 0.001 to 0.15% by weight, based on the total weight of the composition. Further preferred ranges include 0.0001 to 0.1% by weight, 0.0005 to 0.1% by weight, 0.00075 to 0.1% by weight, 0.00075 to 0.1% by weight, 0.001 to 0.1% by weight, 0.005 to 0.1% by weight, 0.01 to 0.1% by weight and 0.01 to 0.1% by weight, 0.001 to 0.05% by weight and 0.01 to 0.05% by weight.

[0021] Preferably, the concentration of mannose used in all embodiments of the present invention is in the range of 0.0001 to 0.5% by weight, more preferably in the range of 0.0005 to 0.25% by weight, most preferably in the range of 0.00075 to 0.2% by weight, for example in the range of 0.001 to 0.15% by weight, based on the total weight of the composition. Further preferred ranges include 0.0001 to 0.1% by weight, 0.0005 to 0.1% by weight, 0.00075 to 0.1% by weight, 0.00075 to 0.1% by weight, 0.001 to 0.1% by weight, 0.005 to 0.1% by weight, 0.01 to 0.1% by weight and 0.01 to 0.1% by weight, 0.001 to 0.05% by weight and 0.01 to 0.05% by weight.

[0022] Preferably, the concentration of fructose used in all embodiments of the present invention ranges from 0.01 to 2% by weight, more preferably from 0.05 to 1% by weight, most preferably from 0.05 to 0.75% by weight, for example, selected in the range of 0.05 to 0.5% by weight, based on the total weight of the composition. Further preferred ranges include 0.01 to 1% by weight, 0.05 to 1% by weight, 0.01 to 0.5% by weight, 0.05 to 0.5% by weight, 0.1 to 1% by weight, and 0.1 to 0.5% by weight.

[0023] Preferably, the concentration of glucose used in all embodiments of the present invention ranges from 0.01 to 3% by weight, more preferably from 0.05 to 2.5% by weight, most preferably from 0.075 to 2% by weight, for example, selected in the range of 0.1 to 1% by weight, based on the total weight of the composition. Further preferred ranges include 0.01 to 1% by weight, 0.05 to 1% by weight, 0.01 to 0.5% by weight, 0.05 to 0.5% by weight, 0.1 to 1% by weight, and 0.1 to 0.5% by weight.

[0024] In all embodiments of the present invention, any isomers of saccharides, i.e., their respective D- and L-isomers and mixtures thereof, can be used. However, in all embodiments, natural ones, i.e., D-isomers, are particularly preferred.

[0025] Preferably, in all embodiments of the present invention, the saccharide is preferably incorporated into the composition of the present invention in the form of an aqueous sugar premix A, and the sugar premix A a) 1 to 5% by weight of psicose based on the sugar premix, and b) 1 to 5% by weight of mannose based on the sugar premix, and c) 10 to 30% by weight of fructose based on the sugar premix, and d) 15 to 60% by weight of glucose based on the sugar premix and contains.

[0026] More preferably, in all embodiments of the present invention, the sugar premix is an aqueous sugar premix B, and the sugar premix B a) 1 to 5% by weight of psicose based on the sugar premix, and b) 1 to 5% by weight of mannose based on the sugar premix, and c) 10 to 30% by weight of fructose based on the sugar premix, and d) 15 to 35% by weight of glucose based on the sugar premix and comprising.

[0027] Most preferably, in all embodiments of the present invention, the aqueous sugar premix is aqueous sugar premix C, and the aqueous sugar premix C is a) 2 to 3% by weight of psicose based on the sugar premix, and b) 1.5 to 3% by weight of mannose based on the sugar premix, and c) 10 to 20% by weight of fructose based on the sugar premix, and d) 20 to 30% by weight of glucose based on the sugar premix and comprising.

[0028] As used herein, the term "sugar premix" refers to a pre-blended mixture containing psicose, mannose, fructose and glucose in the amounts specified herein. The sugar premix can be prepared either by mixing the individual sugars or by isomerization of glucose, preferably plant-derived glucose, prior to incorporation into the composition of the present invention. The aqueous sugar premix preferably contains 25 to 50% by weight of water based on the total of the aqueous premix.

[0029] Isomerization of glucose is well known to those skilled in the art. Preferably, the isomerization process comprises (a) dissolving glucose in water and subsequently (b) isomerizing the glucose at a temperature preferably selected in the range of 25 to 100 °C in the presence of a base, preferably in the presence of sodium hydroxide, and (c) purifying the resulting reaction mixture by chromatography and optionally by filtration.

[0030] In particular, when the sugar premix is prepared by isomerization of glucose, the sugar premix may further contain up to 7.5% by weight, preferably up to 5% by weight, of further saccharides selected from the group of pentoses, hexoses, disaccharides and oligosaccharides, specifically galactose, sorbose and also disaccharides and oligosaccharides. Preferably, the amount of galactose and / or sorbose in the sugar premix of the present invention is selected in the range of 0 to 4% by weight, for example in the range of 1 to 3% by weight. The remaining amount of saccharides contained in the premix are disaccharides and oligosaccharides.

[0031] In certain embodiments, the sugar premix of the present invention further comprises (e) sorbose in an amount selected in the range of 1 to 5% by weight, preferably 1 to 3% by weight, based on the sugar premix.

[0032] Preferably, the use concentration of sorbose in all embodiments of the present invention is selected in the range of 0.0001 to 0.5% by weight, more preferably in the range of 0.0005 to 0.25% by weight, most preferably in the range of 0.00075 to 0.2% by weight, for example in the range of 0.001 to 0.15% by weight, based on the total weight of the composition. Further preferred ranges include 0.0001 to 0.1% by weight, 0.0005 to 0.1% by weight, 0.00075 to 0.1% by weight, 0.00075 to 0.1% by weight, 0.001 to 0.1% by weight, 0.005 to 0.1% by weight, 0.01 to 0.1% by weight and 0.01 to 0.1% by weight, 0.001 to 0.05% by weight and 0.01 to 0.05% by weight.

[0033] In a particularly advantageous embodiment, the sugar premix of the present invention is an aqueous sugar premix, i.e., the saccharides are dissolved in water.

[0034] A particularly preferred aqueous sugar premix (sugar premix D) of the present invention is a) 1 to 5% by weight, preferably 2 to 3% by weight, of psicose, based on the aqueous sugar premix, and b) 1 to 5% by weight, preferably 1.5 to 3% by weight, of mannose, based on the aqueous sugar premix, c) 10 to 30% by weight, preferably 10 to 20% by weight, of fructose, based on the aqueous sugar premix, and d) 15 to 30% by weight, preferably 20 to 30% by weight, of glucose, based on the aqueous sugar premix, and optionally, e) up to 7.5% by weight, preferably up to 5% by weight, of further saccharides, based on the aqueous sugar premix, and f) 0.1 to 2% by weight of additives, preferably citric acid and / or its salts, such as preferably the sodium salt, based on the aqueous sugar premix, and g) up to 100% of water, based on the aqueous sugar premix and consisting essentially of.

[0035] As used herein, the term "consisting essentially of" means that the total amount of components a) to g) ideally totals 100% by weight. However, it is not excluded that, for example, small amounts of unknown (sugar) impurities resulting from the isomerization process of glucose may be present.

[0036] The aqueous sugar premix of the present invention is commercially available, for example, as Pentavitin® from DSM Nutritional Products Ltd.

[0037] The total amount of the sugar premix incorporated into the composition of the present invention is preferably selected in the range of 0.01 to 10% by weight, more preferably in the range of 0.1 to 7.5% by weight, most preferably in the range of 0.2 to 5% by weight, based on the total weight of the aqueous composition. Further suitable ranges are 0.25 to 2.5% by weight and 0.5 to 2% by weight. Particularly preferred ranges according to the present invention are 0.2 to 1% by weight, more preferably 0.25 to 0.75% by weight, for example 0.3 to 0.6% by weight.

[0038] As used herein, the term "dermatological" can refer to both cosmetic (non-therapeutic) and pharmaceutical (therapeutic) treatments. In all embodiments of the present invention, cosmetic treatments, i.e., treatments intended to beautify the skin, are preferred.

[0039] As used herein, the term "cosmetic or dermatological composition" refers to a composition used to treat, care for, or improve the appearance of the skin and / or scalp. Particularly advantageous cosmetic or dermatological compositions are skin care preparations.

[0040] In all embodiments of the present invention, preferably, the cells are skin cells, such as specifically epithelial cells, particularly keratinocytes, melanocytes, fibroblasts or dendritic cells.

[0041] In all embodiments of the present invention, preferably, the treatment is non-therapeutic, i.e., cosmetic.

[0042] Preferably, the amount of the cosmetic or dermatological composition of the present invention for application to the skin is in the range of 0.1 to 3 mg / cm 2 of skin area, for example preferably in the range of 0.1 to 2 mg / cm 2 of skin area, most preferably in the range of 0.5 to 2 mg / cm 2 of skin area is selected.

[0043] In all embodiments of the present invention, preferably, the composition is applied to the skin, specifically preferably before or after exposure or contact to pathogenic bacteria such as S. aureus (S. aureus), preferably before that.

[0044] The cosmetic or dermatological composition of the present invention is intended for topical application, which is understood as topical application, particularly to keratinous substances such as the skin.

[0045] Since the cosmetic or dermatological composition of the present invention is intended for topical application, these contain a physiologically acceptable medium, i.e., a medium that is particularly compatible with keratinous substances such as the skin. In particular, the physiologically acceptable medium is a cosmetically and dermatologically acceptable carrier.

[0046] As used herein, the terms "cosmetically acceptable carrier" or "dermatologically acceptable carrier" refer to a physiologically acceptable medium that is compatible with keratinous substances. Suitable carriers are well known in the art and are selected based on the end use application. Preferably, the carriers of the present invention are suitable for application to the skin (e.g., sunscreen, cream, milk, lotion, mask, serum, hydrodispersion, foundation, cream, cream gel or gel, etc.). Such carriers are well known to those skilled in the art and may include one or more compatible liquid or solid fillers, diluents, excipients, additives or vehicles suitable for application to the skin. The exact amount of the carrier will depend on the concentration of the active substance or active blend and any other optional components (e.g., other active compounds) that would be classified by those skilled in the art as different from the carrier. The cosmetic compositions of the present invention preferably contain from about 70% to about 99.999% by weight, more preferably from about 85% to about 99.99% by weight, even more preferably from 90% to about 99% by weight, and most preferably from about 93% to about 98% by weight of the carrier, based on the weight of the cosmetic composition.

[0047] The cosmetic compositions of the present invention can be formulated into a variety of product types including creams, waxes, pastes, lotions, milks, mousses, gels, oils, tonics and sprays. Preferably, the active substance or active blend is formulated into lotions, creams, gels and tonics. These product forms can be used for several applications including, but not limited to, hand and body lotions, facial moisturizers, anti-aging formulations, cosmetics including foundations. Any additional constituents required to formulate such products will vary depending on the type of product and can be conventionally selected by those skilled in the art.

[0048] Suitable compositions according to the present invention are leave-on or rinse-off products and include any product applied to the human body. Leave-on products are preferred in all embodiments of the present invention.

[0049] As used herein, rinse-off and leave-on are defined by the European Parliament and Council Regulation (EC) No. 1223 / 2009 (as amended) of 30 November 2009 for cosmetic products. That is, a cosmetic product or composition is a rinse-off product or composition if it is intended to be removed after application to the skin, hair or mucous membranes of a human subject, and a leave-on product or composition if it is intended to maintain contact with the skin, hair or mucous membranes for an extended period of time.

[0050] When the cosmetic or dermatological composition of the present invention is formulated as an aerosol and applied to the skin as a spray-type product, a propellant is added to the cosmetic composition.

[0051] The cosmetic or dermatological composition of the present invention can be prepared by conventional methods in the art, such as, for example, by mixing the active substance or active blend of the present invention with a cosmetically acceptable carrier.

[0052] The cosmetic or dermatological composition of the present invention (including the carrier) may contain additional conventional adjuvants and additives such as preservatives / antioxidants, fatty substances / oils, water, organic solvents, silicones, thickeners, softeners, emulsifiers, defoamers, aesthetic constituents such as fragrances, surfactants, fillers, anionic, cationic, nonionic or amphoteric polymers or mixtures thereof, propellants, acidifying or basifying agents, dyes, colorants / coloring agents, abrasives, absorbents, chelating agents and / or sequestering agents, essential oils, skin cooling agents, astringents, pigments or any other components conventionally formulated in such cosmetic or dermatological compositions.

[0053] According to the present invention, the cosmetic or dermatological composition of the present invention may also contain additional cosmetic active ingredients conventionally used in cosmetic and / or dermatological compositions. Exemplary active ingredients include skin whitening agents; UV filters; agents for treating hyperpigmentation; agents for preventing or reducing inflammation; stabilizers, moisturizers, anesthetics and / or activators and agents for improving elasticity and the skin barrier.

[0054] Examples of cosmetic or dermatological excipients, diluents, adjuvants, additives and active ingredients commonly used in the skin care industry, which are suitable for use in the cosmetic or dermatological compositions of the present invention, include, but are not limited to, those described in the International Cosmetic Ingredient Dictionary & Handbook by Personal Care Product Council (http: / / www.personalcarecouncil.org / ), which is accessible, for example, by INFO BASE on the Internet (http: / / online.personalcarecouncil.org / jsp / Home.jsp).

[0055] The additional amounts of active ingredients and excipients, diluents, adjuvants, additives, etc. can be readily determined by those skilled in the art based on the desired product form and use. The additional ingredients can be added to the oily phase, to the aqueous phase or added individually, whichever is considered appropriate.

[0056] Further cosmetic active ingredients useful herein may, in some cases, provide multiple benefits or function via multiple mechanisms of action.

[0057] Of course, those skilled in the art will take care to select the above optional additional ingredients, adjuvants, diluents and additives and / or their amounts such that the advantageous properties inherent in the combination according to the invention are not or are substantially not adversely affected by the envisaged addition(s).

[0058] The cosmetic or dermatological composition of the present invention can be in the form of a suspension or dispersion in a solvent or fatty substance, or alternatively in the form of an emulsion or microemulsion (in particular oil-in-water (O / W), water-in-oil (W / O), silicone-in-water (Si / W) or water-in-silicone (W / Si) type, PIT-emulsion, multiple emulsion (e.g., oil-in-water-in-oil (O / W / O) or water-in-oil-in-water (W / O / W) type), pickering emulsion, hydrogel, alcoholic gel, lipogel, single-phase or multiphase solution or vesicular dispersant), or in other conventional forms that can be applied as a mask or spray by means of a pen.

[0059] When the cosmetic or dermatological composition is an emulsion, for example in particular an emulsion such as O / W, W / O, Si / W, W / Si, O / W / O, W / O / W multiple or pickering emulsion, the amount of the oil phase present in such a cosmetic or dermatological emulsion is preferably at least 10% by weight, for example in the range of 10 - 60% by weight, preferably in the range of 15 - 50% by weight, most preferably in the range of 15 - 40% by weight, based on the total weight of the cosmetic or dermatological composition.

[0060] In one embodiment, the cosmetic or dermatological composition of the present invention is preferably in the form of an oil-in-water (O / W) emulsion comprising an oil phase dispersed in an aqueous phase in the presence of an O / W emulsifier. The preparation of such O / W emulsions is well known to those skilled in the art.

[0061] When the cosmetic or dermatological composition according to the invention is an O / W emulsion, it advantageously contains at least one O / W or Si / W emulsifier selected from the list of glyceryl citrate stearate, glyceryl stearate SE (self-emulsifying), stearic acid, salts of stearic acid, polyglyceryl-3-methylglucose distearate. Further suitable emulsifiers are cetyl phosphate (e.g., as Amphisol® A from DSM Nutritional Products Ltd.), cetyl diethanolamine phosphate (e.g., as Amphisol® DEA from DSM Nutritional Products Ltd.), potassium cetyl phosphate (e.g., as Amphisol® K from DSM Nutritional Products Ltd.), sodium cetearyl sulfate, glyceryl sodium oleate phosphate, hydrogenated vegetable glyceride phosphate and their mixtures, such as esters of phosphoric acid and their salts. Further suitable emulsifiers are sorbitan oleate, sorbitan sesquioleate, sorbitan isostearate, sorbitan trioleate, cetearyl glucoside, lauryl glucoside, decyl glucoside, sodium stearoyl glutamate, sucrose polystearate and hydrated polyisobutene. Further, one or more synthetic polymers can be used as emulsifiers. For example, PVP eicosene copolymer, acrylate / C10-30 alkyl acrylate crosspolymer and their mixtures.

[0062] The at least one O / W or Si / W emulsifier is preferably used in an amount in the range of 0.5 to 10% by weight, in particular in the range of 0.5 to 6% by weight, for example more specifically in the range of 0.5 to 5% by weight, for example most specifically in the range of 1 to 4% by weight, based on the total weight of the cosmetic or dermatological composition.

[0063] Certain suitable O / W emulsifiers for use in the cosmetic or dermatological compositions according to the invention include phosphate esters emulsifiers, such as preferably octyl-10-ethyl phosphate, C9-15 alkyl phosphate, cetearyl-2 phosphate, cetearyl-5 phosphate, ceteth-8 phosphate, ceteth-10 phosphate, cetyl phosphate, C6-10 pareth-4 phosphate, C12-15 pareth-2 phosphate, C12-15 pareth-3 phosphate, cetearyl-2 phosphate DEA, cetyl phosphate DEA, oleth-3 phosphate DEA, potassium cetyl phosphate, deceth-4 phosphate, deceth-6 phosphate and trilauryl-4 phosphate.

[0064] A particularly suitable O / W emulsifier for use in the cosmetic or dermatological compositions according to the invention is, for example, potassium cetyl phosphate, which is commercially available as Amphisol® K from DSM Nutritional Products Ltd Kaiseraugst.

[0065] Another particularly suitable class of O / W emulsifiers is, for example, the non-ionic self-emulsifying system derived from olive oil, known as (INCI name) cetearyl olive oil fatty acid and sorbitan olive oil fatty acid (chemical composition: sorbitan esters and cetearyl esters of olive oil fatty acids) and sold under the trade name OLIVEM 1000.

[0066] In a particular embodiment, the invention relates to a cosmetic or dermatological composition in the form of an O / W emulsion comprising an oil phase dispersed in an aqueous phase in the presence of an O / W emulsifier, the definition and preferences of which are all as indicated herein, and the O / W emulsifier is potassium cetyl phosphate. The amount of the oil phase in such an O / W emulsion is preferably at least 10% by weight, more preferably in the range of 10-60% by weight, most preferably in the range of 15-50% by weight, for example in the range of 15-40% by weight.

[0067] The cosmetic or dermatological composition of the present invention generally has a pH in the range of 3 to 10, preferably in the range of 4 to 8, and most preferably in the range of 4 to 7.5. The pH can be easily adjusted as needed by suitable acids such as citric acid or bases such as sodium hydroxide (e.g., as an aqueous solution), triethanolamine (TEA Care), tromethamine (Trizma Base), and aminomethylpropanol (AMP-Ultra PC2000) according to standard methods in the art.

[0068] The following examples are provided to further illustrate the effects of the present invention. These examples are for illustration only and are not intended to limit the scope of the present invention in any way.

[0069] [Examples] The experiment was designed to investigate the skin and microbiome protection effects of a sugar blend containing psicose, mannose, fructose, and glucose by evaluating skin integrity by immunostaining of cytokeratin 1 after pathogen colony formation of S. aureus.

[0070] [Test Substances] The following substances were topically applied to 3D skin tissue. · Vehicle control (ultrapure water) · Sugar premix (prepared by isomerizing plant-derived glucose at 1% in ultrapure water; (approx. 25% glucose, 15% fructose, 2% mannose, 2.5% psicose, and 50% water)

[0071] [Methods] [1. Preparation of 3D Skin] Primary adult human skin fibroblasts were embedded in a fibrin matrix to generate a skin equivalent (DE). The matrix was remodeled by the fibroblasts by culturing the DE. Primary neonatal human keratinocytes were applied to the surface of the DE and cultured under liquid for 48 hours. The 3D skin was cultured at the gas-liquid interface until a stratified epidermis was formed. For all culture media, the incubation conditions were 5% (v / v) CO at >95% RH2 It was 37°C.

[0072] [2. Test procedure] Throughout the study, 3D skin was maintained in deep well plates. The maintenance medium was changed on the day when the symbiotic consortium formed colonies.

[0073] 2.1. Using reinforced Clostridium agar medium, Cutibacterium acnes NCTC 737 was anaerobically cultured at 37°C for 5 days.

[0074] 2.2. Staphylococcus epidermidis NCTC 11047 and Corynebacterium striatum NCTC 764 were aerobically cultured for 18 - 24 hours using Mueller - Hinton agar and aerobic Corynebacteria agar respectively.

[0075] 2.3. Using inoculation buffer GS25 and bacteria from the above - mentioned culture solutions, a primary inoculant mix containing each bacterium at approximately 1.1×106 cfu mL-1 was prepared (3× mix consortium).

[0076] 2.4. Using 10 μL of the primary inoculant, approximately 104 cfu cm -2 of bacteria were allowed to form colonies on each 3D skin unit.

[0077] 2.5. The 3D skin was cultured at 37°C in 5% (v / v) CO2 with >95% RH for approximately 2 hours (until the surface of the 3D skin dried).

[0078] 2.6. The 3D skin units with colonies formed were treated with either 10 μL of each test article or the vehicle control.

[0079] 2.7. The 3D skin was cultured at 37°C in 5% (v / v) CO 2It was incubated at 37°C for approximately 24 hours.

[0080] 2.8. On the same day when colonies were formed on 3D skin with 3×mix, Staphylococcus aureus strain NCTC 13435 was aerobically cultured at 37°C for 18 - 24 hours in Mueller - Hinton agar.

[0081] 2.9. Using bacteria from the overnight culture of the above - mentioned Staphylococcus aureus type strain NCTC 13435, a stock bacterial suspension in buffer GS25 was prepared.

[0082] 2.10. 3D skin that had been pre - colonized with 3×mix at 1×104 cfu / cm 2 was infected with S. aureus at 102 cfu / cm−2.

[0083] 2.11. The colonized 3D skin was incubated at 37°C for approximately 48 hours in 5% (v / v) CO2 with >95% RH.

[0084] Approximately 72 hours after treatment with the test article, the tissue was fixed in 10% neutral buffered formalin, processed, embedded in paraffin, and sectioned. Immunohistochemical examination and staining quantification were performed for cytokeratin 1 expression in the tissue (three test samples: untreated, vehicle control, and sugar premix).

[0085] Results (tissue structure): Cytokeratin expression compared with untreated

Table 1

[0086] The results show that a blend of 1% saccharides increased the tissue expression of cytokeratin-1 in skin fibroblasts colonized with C. acnes, S. Epidermidis, C. striatum and S. aureus by 68% compared to the expression obtained in samples treated with vehicle control only.

Claims

1. The cosmetic use of a composition comprising an effective amount of a blend of saccharides including psicose, mannose, fructose and glucose in dermatological treatment as an agent for increasing the expression of cytokeratin 1 in skin tissue, wherein the skin microbiome comprises one or more of C. acnes, S. Epidermidis, C. striatum and S. aureus, or the skin microbiome of the skin comprises one or more of C. acnes, S. Epidermidis and C. striatum and is exposed or potentially exposed to S. aureus. Cosmetic use.

2. The cosmetic use according to claim 1, wherein the blend of saccharides is used to enhance the self - defense mechanism of the skin and maintain the skin integrity of the skin.

3. The cosmetic use according to claim 1 or 2, wherein the composition is applied to the skin before exposure to S. aureus, followed by contact between the skin and S. aureus.

4. The effective amount of psicose is selected in the range of 0.0001 to 0.5% by weight, preferably 0.005 to 0.25% by weight, most preferably 0.0075 to 0.2% by weight based on the total weight of the composition. The cosmetic use according to any one of claims 1 to 3.

5. The effective amount of mannose is selected in the range of 0.001 to 0.5% by weight, preferably 0.005 to 0.25% by weight, most preferably 0.0075 to 0.2% by weight based on the total weight of the composition. The cosmetic use according to any one of claims 1 to 4.

6. The effective amount of fructose is selected in the range of 0.01 to 2% by weight, preferably 0.05 to 1% by weight, and most preferably 0.05 to 0.75% by weight based on the total weight of the composition, for the cosmetic use according to any one of claims 1 to 5.

7. The effective amount of glucose is selected in the range of 0.01 to 3% by weight, preferably 0.05 to 2.5% by weight, and most preferably 0.075 to 2% by weight based on the total weight of the composition, for the cosmetic use according to any one of claims 1 to 6.

8. The saccharide is an aqueous premix, and based on the total weight of the premix, a) 1 to 5% by weight, preferably 2 to 3% by weight of psicose, and b) 1 to 5% by weight, preferably 1.5 to 3% by weight of mannose, and c) 10 to 30% by weight, preferably 10 to 20% by weight of fructose, and d) 15 to 30% by weight, preferably 20 to 30% by weight of glucose are incorporated into the composition in the form of an aqueous premix containing them, for the cosmetic use according to any one of claims 1 to 7.

9. The premix is obtained by isomerization of plant-derived glucose, for the cosmetic use according to claim 8.

10. A method for preventing or treating skin diseases caused by a decrease in the expression of cytokine 1 in the skin, wherein the skin microbiome is C. acnes, S. epidermidis and C. striatum, and the skin is to be exposed to S. aureus, and the method comprises: a) providing a topical composition comprising a blend of saccharides including psicose, mannose, fructose and glucose; b) applying an amount of the topical composition sufficient to increase cytokine 1 expression to human skin or scalp, and subsequently, c) exposing the skin to S. aureus; and A method comprising: **Claim 11** A method of treating a skin disease, wherein a decrease in cytokeratin 1 expression contributes to the pathology, and / or symptoms, and / or progression of the skin disease, wherein the skin microbiome is C. acnes, S. epidermidis, C. striatum, and / or S. aureus, or the skin microbiome of the skin comprises one or more of C. acnes, S. epidermidis, and C. striatum and is exposed or potentially exposed to S. aureus, the method comprising administering to a subject in need thereof an effective amount of a blend of saccharides comprising psicose, mannose, fructose, and glucose. **Claim 12** A method of enhancing the skin's self-defense mechanism and maintaining skin integrity in the skin, wherein the skin microbiome is C. acnes, S. epidermidis, C. striatum, and / or S. aureus, or the skin microbiome of the skin comprises one or more of C. acnes, S. epidermidis, and C. striatum and is exposed or potentially exposed to S. aureus, the method comprising applying to a skin area in need of such enhancement an effective amount of a blend of saccharides comprising psicose, mannose, fructose, and glucose. **Claim 13** Cosmetic use of a blend of saccharides comprising psicose, mannose, fructose and glucose as a cytokeratin 1 promoter in the skin, wherein the skin microbiome comprises one or more of C. acnes, S. Epidermidis, C. striatum and S. aureus, or the skin microbiome comprises one or more of C. acnes, S. Epidermidis and C. striatum and is exposed or potentially exposed to S. aureus, cosmetic use.

Images